PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R

Xiong,Ting; Wei,Heng; Chen,Xiaoqiong; Xiao,Hui

doi:10.3892/ijo.2014.2726

PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R

Authors:
- Ting Xiong
- Heng Wei
- Xiaoqiong Chen
- Hui Xiao
View Affiliations

Affiliations: Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: October 23, 2014 https://doi.org/10.3892/ijo.2014.2726
Pages: 223-232

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is still no ideal treatment for multidrug resistant multiple myeloma, looking for drugs which can reverse chemotherapy resistance and enhance curative effects of chemotherapy drugs becomes a problem that needs to be solved urgently. Poly(ADP-ribose) polymerase inhibitors appear to be an important tool for medical therapy of several malignancies. In the present study, we investigated the potential of the PARP-1 inhibitor PJ34, in vitro, to further enhance the efﬁcacy of the traditional chemotherapy drug melphalan in the multidrug-resistant multiple myeloma cell line RPMI8226/R. The effects of different concentrations of PJ34 and melphalan on cell proliferation were determined by the CCK-8 assay. The expressions of FA/BRCA pathway-related factors were detected by western blotting and RT-PCR. The percentage of cell apoptosis was measured with flow cytometry. DNA double-strand break (DSB) repair was quantiﬁed by γH2AX immunoﬂuorescence. In addition, DNA damage repair at the level of the individual cell was determined by comet assay. Co-administration of PJ34 and melphalan had synergistic inhibitory effects on the proliferation of RPMI8226/R cells, suggesting more powerful antitumor activities. The apoptosis percentage also was increased more obviously by the treatment of melphalan plus PJ34. The activation of FA/BRCA pathway was inhibited by downregulation of related factors including FANCD2, BRCA2 and Rad51. PJ34 significantly increased the ratio of γH2AX-positive cells and the number of foci/cells. The comet tail rate of cells, tail length, tail moment and Olive tail moment all increased after PJ34 treatment in RPMI8226/R cells. These results indicate that PJ34 combined treatment with melphalan produces synergistic effects and reverses multidrug resistance of RPMI8226/R cells effectively. PJ34 cannot induce DNA damage directly, but it may increase the DNA damage induced by melphalan through inhibiting DNA damage repair. The suppression of FA/BRCA pathway may be the mechanism. Therefore, we suggest that PARP inhibitors may deserve future investigations as tools for medical treatment of multidrug resistant multiple myeloma.

View Figures

View References

1	Spanswick VJ, Lowe HL, Newton C, et al: Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer. 12:4362012. View Article : Google Scholar
2	Bouwman P and Jonker J: The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 12:587–598. 2012. View Article : Google Scholar : PubMed/NCBI
3	Altieri F, Grillo C, Maceroni M, et al: DNA damage and repair: from molecular mechanisms to health implications. Antioxid Redox Signal. 10:891–937. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hlavin EM, Smeaton MB and Miller PS: Initiation of DNA interstrand cross-link repair in mammalian cells. Environ Mol Mutagen. 51:604–624. 2010.PubMed/NCBI
5	Bessho T: Induction of DNA replication-mediated double strand breaks by psoralen DNA interstrandcross-links. J Biol Chem. 278:5250–5254. 2003. View Article : Google Scholar : PubMed/NCBI
6	Sczepanski JT, Jacobs AC, Van Houten B, et al: Double-strand break formation during nucleotide excision repair of a DNA interstrand cross-link. Biochemistry. 48:7565–7567. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kim H and D’Andrea AD: Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 26:1393–1408. 2012. View Article : Google Scholar : PubMed/NCBI
8	Mouw KW and D’Andrea AD: Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways. DNA Repair. 19:130–134. 2014. View Article : Google Scholar : PubMed/NCBI
9	Levitus M, Joenje H and de Winter JP: The Fanconi anemia pathway of genomic maintenance. Cell Oncol. 28:3–29. 2006.PubMed/NCBI
10	Cohn MA and D’Andrea AD: Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways. Mol Cell. 32:306–312. 2008. View Article : Google Scholar : PubMed/NCBI
11	Rodríguez A, Sosa D, Torres L, et al: A Boolean network model of the FA/BRCA pathway. Bioinformatics. 28:858–866. 2012.
12	Karanja KK, Cox SW, Duxin JP, et al: DNA2 and EXO1 in replication-coupled, homology-directed repair and in the interplay between HDR and the FA/BRCA network. Cell Cycle. 11:3983–3996. 2012. View Article : Google Scholar : PubMed/NCBI
13	Stecklein SR and Jensen RA: Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. Transl Res. 160:178–197. 2012. View Article : Google Scholar : PubMed/NCBI
14	Jacquemont C, Simon JA, D’Andrea AD, et al: Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer. 11:262012. View Article : Google Scholar : PubMed/NCBI
15	Chirnomas D, Taniguchi T, de la Vega M, et al: Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 5:952–961. 2006. View Article : Google Scholar : PubMed/NCBI
16	Taniguchi T and D’Andrea AD: Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 107:4223–4233. 2006. View Article : Google Scholar : PubMed/NCBI
17	Mori R, Yoshida K, Tanahashi T, et al: Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells. Gastric Cancer. 16:345–354. 2013. View Article : Google Scholar : PubMed/NCBI
18	Deans AJ and West SC: DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 11:467–480. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hegi ME, Sciuscio D, Murat A, et al: Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res. 15:5026–5031. 2009. View Article : Google Scholar : PubMed/NCBI
20	Palagyi A, Neveling K, Plinninger U, et al: Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer. 9:1272010. View Article : Google Scholar
21	Burkitt K and Ljungman M: Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol Cancer. 7:242008. View Article : Google Scholar : PubMed/NCBI
22	Kondo N, Takahashi A, Mori E, et al: FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ. PLoS One. 6:e196592011. View Article : Google Scholar : PubMed/NCBI
23	Yarde DN, Oliveira V, Mathews L, et al: Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 69:9367–9375. 2009. View Article : Google Scholar : PubMed/NCBI
24	Adhikari S, Choudhury S, Mitra PS, et al: Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem. 8:351–357. 2008. View Article : Google Scholar : PubMed/NCBI
25	David KK, Andrabi SA, Dawson TM, et al: Parthanatos, a messenger of death. Front Biosci. 14:1116–1128. 2009. View Article : Google Scholar : PubMed/NCBI
26	Wang Y, Dawson VL and Dawson TM: Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol. 218:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
27	Bryant HE, Petermann E, Schultz N, et al: PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 28:2601–2615. 2009. View Article : Google Scholar : PubMed/NCBI
28	Krishnakumar R and Kraus WL: The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 39:8–24. 2010. View Article : Google Scholar : PubMed/NCBI
29	Węsierska-Gądek J, Zulehner N, Ferk F, et al: PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells. Biochem Pharmacol. 84:1318–1331. 2012.PubMed/NCBI
30	Lavarone E, Puppin C, Passon N, et al: The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines. Mol Cell Endocrinol. 365:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
31	Davidson D, Wang Y, Aloyz R, et al: The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Invest New Drugs. 31:461–468. 2013. View Article : Google Scholar : PubMed/NCBI
32	Cheng H, Zhang Z, Borczuk A, et al: PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. 34:739–749. 2013. View Article : Google Scholar : PubMed/NCBI
33	Cavallo F, Graziani G, Antinozzi C, et al: Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to cisplatin and poly (ADP-ribose) polymerase inhibition. PLoS One. 7:e515632012. View Article : Google Scholar
34	Donawho CK, Luo Y, Luo Y, et al: ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 13:2728–2737. 2007. View Article : Google Scholar : PubMed/NCBI
35	Ahel I, Ahel D, Matsusaka T, et al: Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature. 451:81–85. 2008. View Article : Google Scholar : PubMed/NCBI
36	Pyriochou A, Olah G, Deitch EA, et al: Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med. 22:113–118. 2008.PubMed/NCBI
37	Xiao H, Xiao Q, Zhang K, et al: Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol. 89:399–404. 2010. View Article : Google Scholar : PubMed/NCBI
38	Vinod BS, Maliekal TT and Anto RJ: Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance. Antioxid Redox Signal. 18:1307–1348. 2013. View Article : Google Scholar : PubMed/NCBI
39	Tomicic MT and Kaina B: Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim Biophys Acta. 1835:11–27. 2013.PubMed/NCBI
40	Liu X, Luo X, Shi Y, et al: Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. Cancer Biol Ther. 7:934–941. 2008. View Article : Google Scholar : PubMed/NCBI
41	Gambi N, Tramontano F and Quesada P: Poly(ADPR) polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines. Biochem Pharmacol. 75:2356–2363. 2008. View Article : Google Scholar : PubMed/NCBI
42	Yang YG, Cortes U, Patnaik S, et al: Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene. 23:3872–3882. 2004. View Article : Google Scholar : PubMed/NCBI
43	Mah LJ, Orlowski C, Ververis K, et al: Utility of γH2AX as a molecular marker of DNA double-strand breaks in nuclear medicine: applications to radionuclide therapy employing auger electron-emitting isotopes. Curr Radiopharm. 4:59–67. 2011. View Article : Google Scholar
44	Richardson C: RAD51, genomic stability, and tumorigenesis. Cancer Lett. 218:127–139. 2005. View Article : Google Scholar : PubMed/NCBI
45	Klein HL: The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair. 7:686–693. 2008. View Article : Google Scholar : PubMed/NCBI
46	Qiao GB, Wu YL, Yang XN, et al: High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer. 93:137–143. 2005. View Article : Google Scholar : PubMed/NCBI
47	Luoto KR, Meng AX, Wasylishen AR, et al: Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res. 70:8748–8759. 2010. View Article : Google Scholar : PubMed/NCBI